U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799234) titled 'Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)' on Sept. 20, 2024.
Brief Summary: The goal of this clinical trial is to learn if ChAdOx1 RVF, a candidate vaccine against RVF, provides an adequate immune response and determine its safety among Kenyan adults. The main aims are:
* To assess the proportion of individuals mounting an immune response following vaccination with a single dose of ChAdOx1 RVF
* To monitor occurrence of any adverse events following vaccination
* To assess whether two doses of ChAdOx1 RVF elicit an immune response that is more durable than that generated by a single dose of ChAdO...